It is well to be noted that in a potential big advancement when it comes to oncology treatment as well as information sharing, many leading electronic health record vendors have gone on to make a voluntary commitment so as to adopt the United States Core Data for Interoperability Plus Cancer- USCDI+ Cancer, a kind of a recommended minimum set of major cancer-related data aspects that need to be included in a patient’s EHR.

They have also gone on to pledge to support the required data elements for a new cancer care payment model which is developed by the Centers for Medicare and Medicaid Services.

Notably, the Cancer Moonshot Initiative, which happened to be first launched in 2016 and thereafter resurrected in 2022, happens to be a multipronged effort that looks forward to lowering costs as well as improving patient care and outcomes for cancer patients, and it goes on to require the EHRs to take into account interoperability along with new data standards.

As per the White House Office of Science and Technology Policy blog, in sync with the National Institutes of Health, Department of Health, and Human Services Office of the National Coordinator for Health Information Technology, CMS, as well as the Cancer Moonshot, the EHR developers group voluntarily went on to commit to adopting data elements that take into account the vital information about a person’s treatment history, disease status, as well as test results so as to improve data sharing by healthcare providers.

The administration went on to say that the adoption by Oracle Health, Epic, Meditech, Flatiron, athenahealth, ThymeCare, Ontada, and CVS Health EHRs will go on to enhance care coordination among the people facing cancer across the country, specifically in rural and underserved areas. Standardizing data all throughout the EHRs also opens up new possibilities for rapid research results as well as more effective public health interventions.

Due to the fact that the EOM data elements also go on to form the core of USCDI+ Cancer, a minimum set of key cancer-related data elements is recommended so as to be included in a patient’s EHR. The administration remarked that it is calling upon the whole healthcare ecosystem to push forward national health information exchange.

Health data as well as research have, for quite a long period of time, been trapped in silos, said former President Barack Obama in January 2016, a time when he announced the Cancer Moonshot within his final State of the Union Address and, as a matter of fact, appointed then Vice President Joe Biden to take charge of it.

At that time, he had said that only 5% of cancer patients across the U.S. went on to end up in a clinical trial.

Obama had remarked that most are not given access to their own data, and at the same time, community oncologists, who happen to treat over 75% of cancer patients, happen to be having a limited access in terms of cutting-edge research as well as advances.

That number has now gone up, as per the research that has been published in the Journal of Clinical Oncology in 2021.

Apparently by 2020, a minimum of 25.4% of adult cancer patients happened to be estimated to participate in one or more than one cancer clinical research study, said the researchers, thereby concluding that based on the enrollment data coming from the Commission on Cancer, the enrollment in cancer treatment trials happened to be 6.3%, higher as compared to the historical estimates of <5%.

As a matter of fact, now FHIR-based oncology data exchange via the EOM could enhance oncology delivery for the time to come, said Jennifer Goldsack from the Digital Medicine Society.

As per her, harnessing the power when it comes to digital innovation so as to achieve the objective of reducing cancer deaths by half becomes much more possible when data happens to be flowing.

She adds that data does not happen to live in a manilla folder within a file cabinet with either only the practice manager or probably the principal investigator of a clinical trial having access.

With the exact interoperability specifications and also privacy, security can go on to fundamentally change how one delivers healthcare, said, Goldsack.

They have been talking about learning health systems as well as precision medicine for decades, but the time now is when they can deliver.

The deputy assistant to the President for the Cancer Moonshot, Dr. Danielle Carnival, said that these commitments are not to them but to the people who happen to rely on these electronic health record systems, such as those providers as well as patients. He went on to add that they commend such a voluntary action from the leaders in the electronic health record developer community, as it goes on to help the clinicians provide enhanced treatment for people with cancer.

In a recent move, the US President Joe Biden happens to be taking on a bipartisan bogeyman prior to the crucial State of the Union speech, stressing the pharmaceutical industry as well as saying that he will work towards expanding the government’s power to lower drug prices.

In a fact sheet that has been released on March 6, the White House remarked that Medicare should be allowed in order to negotiate prices for 50 medications per year. That would be a prominent jump from the limit of 20 within the Inflation Reduction Act- IRA.

It is well to be noted that President Biden is also looking forward to expanding a $2,000 cap on out-of-pocket drug expenses towards private insurers, thereby extending a $2 cost-sharing limit for high-value generic drugs across all the Medicare plans and, at the same time, widening requirements in terms of rebates when price rises exceed inflation. The White House, apart from this, listed a series of prominent novel endeavors that would go on to affect health insurance, research, as well as home care.

With the fact that the national polls show Biden trailing former President Trump, the State of the Union address is taking on outsized significance. Biden is going to be working to remind Americans of his office accomplishments and go on to persuade them that he can get even more done as far as another four years are concerned.

Both Republicans as well as Democrats go on to overwhelmingly favor more regulation in terms of prescription drug prices, as per the polling by KFF. Due to the IRA, Biden’s administration happens to be the first to have the authority so as to negotiate prices on behalf of Medicare, as well as began that process in August by way of releasing the list of the first 10 drugs that would enter talks.

The pharmaceutical sector says the negotiation provision of the 2022 law will go on to chill innovation, with the administration facing a number of lawsuits right before the list of targeted drugs even came out. Apparently, PhRMA as well as AstraZeneca have already gone on to lose their initial legal bids, while there are four drugmakers which happen to be making oral arguments at a court in New Jersey.

Apparently, the White House has gone on to say that the manufacturers of all 10 drugs that have been selected for the first round of negotiations go on to remain at the table after submitting counteroffers. The administration looks to announce the new prices later this year. The CMS, under the law, can go ahead and add another 15 drugs for negotiation in 2027 as well as 2028, another 20 in 2029, and thereafter each year post-2029.

Although raising that figure to 50 will undoubtedly hurt pharma profits, analysts are kind of skeptical that Biden’s proposals will go on to become reality under what is likely to be a divided government in Washington. And in spite of the initial dire warnings issued by the sector with regards to the consequences of negotiation, many executives have recently indicated the effects may as well not be too onerous, analyst from Leerink, David Risinger wrote in a note to clients on March 6.

Brian Abrahams, the analyst from RBC Capital Markets, opines that while rhetoric and headlines going into the election can go on to create some transient volatility within the space, they will not expect most investors to be overwhelmingly spooked by such developments.

It is worth noting that the US Food and Drug Administration- FDA has recently gone on to highlight the data integrity issues that concern the premarket submissions received in case of medical devices.

The agency has gone on to declare that it has identified a surge in terms of fraudulent as well as unreliable laboratory testing data within such submissions.

It has gone ahead and advised manufacturers, along with the study sponsors, for these products to make sure to carefully gauge the third parties they happen to engage with so as to conduct performance testing and to independently double-check all testing results prior to submitting them to the FDA.

Making sure of the data integrity of medical devices

The FDA went on to stress that these firms are indeed responsible for qualifying third parties that go on to generate data as well as ensuring that all the data that’s submitted to the FDA happens to be truthful as well as accurate.

In recent years, there has indeed been a rising trend in which the entities that happen to contract with the device firms so as to conduct testing on medical devices are going ahead and generating testing data that is either fabricated, duplicated from certain other device submissions, or otherwise unreliable, noted the organization.

Since it takes into account the data integrity of the overall file, the FDA asserted that it is unable to depend on the data so as to grant marketing authorization.

The FDA, as such, highlighted that all the testing data that a firm does not perform itself must be examined, specifically the one that’s relating to biocompatibility as well as other performance testing.

The agency went on to acknowledge that it may be pretty challenging for individual device firms so as to confirm if specific data has been taken from a marketing submission that’s unrelated. But it also expects device firms to take into consideration the testing results that happen to be improbable or impossible on their face or are inconsistent with known data pertaining to the device.

So as to make sure that the medical devices happen to be safe, effective, and high-quality, in its letter, the FDA went on to state that it is taking many actions in order to identify as well as confront data integrity violations.

In its entirety, the FDA asked the medical device sector to be more vigilant as well as proactive when it comes to making sure of the integrity of all data that they go ahead and include in medical device submissions.

Making sure of the safety and efficacy of medical devices

The UK perspective

Medical Devices and IVDs Regulatory Quality and Clinical Consultant, Shweta Agarwal, commented about a recent MedTech Regulatory Reform webinar conducted by the MHRA.

Taking her perspective into account, when considering the future of medical device regulations within the UK, the updates go on to reflect a proactive approach to regulatory reform, thereby prioritizing safety as well as efficacy in terms of medical device development.

Especially it is the MHRA that is taking steps so as to sync with the scope of medical device regulations having international practices, especially the EU medical device regulation- MDR. All this goes on to mean updating definitions in terms of medical devices so as to ensure consistency across borders.

Besides this, Agarwal went on to note positively that the essential needs shall be aligned with general safety as well as performance requirements- GSPRs of the EU MDR, thereby making sure that stringent standards are met.

Finally, the fact is that it is indeed clear that US as well as UK regulators happen to be working so as to streamline guidelines to make sure of the quality and also the safety of medical devices that happen to be made available.